Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
Saved in:
| Title: | Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo. |
|---|---|
| Authors: | Blazevic A; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Edwards RL; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Xia M; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Eickhoff CS; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Hamzabegovic F; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Meza KA; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Ning H; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Tennant J; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Mosby KJ; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri., Ritchie JC; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Girmay T; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Lai L; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., McCullough M; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Beck A; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Kelley C; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Edupuganti S; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Kabbani S; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Buchanan W; Division of Microbiology, Immunology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Makhene MK; Division of Microbiology, Immunology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Voronca D; The Emmes Company, LLC, Global Head Biomedical Data Science and Bioinformatics, Rockville, Maryland., Cherikh S; The Emmes Company, LLC, Global Head Biomedical Data Science and Bioinformatics, Rockville, Maryland., Goll JB; The Emmes Company, LLC, Global Head Biomedical Data Science and Bioinformatics, Rockville, Maryland., Rouphael NG; Hope Clinic, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia., Mulligan MJ; Grossman School of Medicine, NewYork University., Hoft DF; Department of Internal Medicine, School of Medicine, Saint Louis University, Missouri. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 May 15; Vol. 229 (5), pp. 1498-1508. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
